Long term complete remission of severe nephrotic syndrome secondary to diffuse global (IV-G) lupus nephritis following autologous,haematopoietic peripheral stem (CD34+) cell transplantation

Abstract

Autologous haematopoietic stem cell transplantation has become an accepted powerful therapeutic procedure for patients with severe, intractable SLE. Here we describe a 26-year old patient with stage IV-G diffuse global proliferative lupus nephritis and refractory nephrotic syndrome who responded to autologous peripheral stem cell transplantation (ASCT) after two mobilization procedures. Five years later the patient is in complete clinical and immunologic remission. The indications for ASCT and its mechanism of action are briefly discussed.

Keywords

autologous stem cell transplantation lupus nephritis nephrotic syndrome

Get full access to this article

View all access options for this article.

References

Marmont AM. Perspective. Immunoablation with stem cell rescue: a possible cure for systemic lupus erythematosus . Lupus 1993; 2: 19-156 .

Tyndall A , Fassas A , Passweg J et al. Autologous haematopoietic stem cell transplant for autoimmune disease-feasability and transplant-related mortality . Bone Marrow Transplant 1999; 24: 729-734 .

Marmont AM , van Lint MT , Gualandi F , Bacigalupo A. Autologous stem cell transplantation for severe systemic lupus erythematosus of long duration . Lupus 1997; 6: 545-548 .

Traynor AE , Barr WG , Rosa RM et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients . Arthritis Rheum 2002; 46: 2917-2923 .

Jayne D , Passweg, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus . Lupus 2004; 13: 168-173 .

Starkute L , Traynor A , Oyama Y et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation . Blood 2005; 106: 2702-2711 .

Gualandi F. , Marmont A. M. , Mancardi G. L. et al. Stem cell transplantation for severe autoimmune diseases. A single-centre experience . Bone Marrow Transplant 2005; 35(suppl. 2): 231-232 .

Raiola AM , van Lint MT , Lamparelli T et al. Reduced intensify thiotepa-cyclophosphamide conditioning for allogenic haematopoietic stem cell transplantation (HSCT) in patients upto 60 years of age . Br J Haematol 2000; 109: 716-772 .

Gratwohl A , Passweg J , Bocelli-Tyndall C et al. Autologous hematopoieitc stem cell transplantation for autoimmune diseases . Bone Marrow Transplant 2005; 35: 869-879 .

10.

Burt RK , Fassas A , Snowden J et al. Collection of hematopoietic stem cells from patients with autoimmune diseases . Bone Marrow Transplant 2001; 28: 1-12 .

11.

Sun W , Popat U , Hutton G et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis . Brain 2004; 127: 996-1008 .

12.

Muraro P , Douek DC , Packer A et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients . J Exper Med 2005; 201: 805-816 .

13.

Hinterberger W , Hinterberger-Fischer M , Marmont A. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases . Bone Marrow Transplant 2002; 30: 753-759 .

14.

Sykes M , Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation . Nature 2005; 435: 620-627